High-flow Nasal Oxygen Therapy to Prevent Extubation Failure in Adult Trauma Intensive Care Patients

Launched by HAMAD MEDICAL CORPORATION · Oct 26, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating whether high-flow nasal oxygen therapy (HFNO) can help prevent complications when patients who have been intubated for trauma-related injuries are taken off the breathing tube. When these patients are extubated, some may need to have the tube reinserted, which can lead to longer hospital stays and increased health risks. The study will compare the effectiveness of HFNO to standard oxygen therapy and another method called non-invasive ventilation. Researchers want to see if using HFNO after extubation can reduce the need for re-intubation and improve overall recovery.

To participate in this study, patients must be adults who are currently intubated and ventilated due to trauma and are deemed ready to be extubated. However, those who cannot be safely extubated or have specific injuries, like certain facial fractures, will not be eligible. If a patient participates, they will be randomly assigned to one of three groups, receiving either standard oxygen, HFNO, or non-invasive ventilation for 24 hours after being taken off the tube. This trial is currently recruiting participants, and the goal is to find better ways to help patients recover after serious injuries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult intubated and ventilated patients who are victims of trauma and are being cared for on the Trauma Intensive Care Unit will be considered eligible for the study when they are considered fit for extubation.
• Exclusion Criteria:
• • Patients who cannot be extubated (including patients requiring tracheostomy)
• • Patients with cribriform plate fractures
• • Patients with nasal occlusion for any reason
• • Patients with unstable mid-face fractures